$44M Settlement In COVID-19 Vaccine Securities Suit Gets Final Approval
PHILADELPHIA — A federal judge in Pennsylvania granted final approval to a settlement of more than $44 million in a securities class lawsuit against a biotechnology company and three of its...To view the full article, register now.
Already a subscriber? Click here to view full article